There are currently 979 clinical trials in San Antonio, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Health Science Center at San Antonio, GSK Investigational Site, Pfizer Investigational Site and Methodist Children's Hospital of South Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
NCT06667141
Recruiting
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Specific Advanced Solid Tumors
Register for Updates
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556
Recruiting
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from partici... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Urology San Antonio, San Antonio, Texas
Conditions: Metastatic Hormone-sensitive Prostate Cancer
Register for Updates
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT07003425
Recruiting
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period. This study will be conducted in participants with atopic de... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Investigational Site, San Antonio, Texas
Conditions: Atopic Dermatitis
Register for Updates
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
08/12/2025
Locations: Gastroenterology Research of America, LLC, San Antonio, Texas
Conditions: Moderately to Severely Active Crohns Disease
Register for Updates
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
08/12/2025
Locations: Carta - Clinical Associates In Research Therapeutics Of America;LLC, San Antonio, Texas
Conditions: Moderately to Severely Active Crohns Disease
Register for Updates
Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation
NCT06892340
Recruiting
The purpose of this research study is to learn how a wearable nerve stimulation device, the Spark Biomedical's Sparrow Ascent System™, impacts the development of spatial disorientation and/or motion sickness in a healthy population. Spatial disorientation is when there is a "mismatch" between where a person is, and where the sense organs in their body tell them where they are. These sense organs include the inner ear (the vestibular system), the eyes (the visual system), the sense of where one'... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
08/12/2025
Locations: Randolph AFB Physiology lab, San Antonio, Texas
Conditions: Motion Sickness
Register for Updates
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
NCT06824987
Recruiting
The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/12/2025
Locations: Research Site, San Antonio, Texas
Conditions: APOL1-Mediated Kidney Disease
Register for Updates
A Study of RM-718 in Healthy Subjects and in Patients With HO
NCT06239116
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with hypothalamic obesity (HO).
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
08/12/2025
Locations: Worldwide Clinical Trials, San Antonio, Texas
Conditions: Hypothalamic Obesity
Register for Updates
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
NCT06428396
Recruiting
The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) unresectable metastatic breast cancer. There is no formal hypothesis testing in this study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Mays Cancer Center ( Site 0022), San Antonio, Texas
Conditions: Metastatic Breast Cancer
Register for Updates
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This eve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/12/2025
Locations: UT Health - San Antonio- Site Number : 8401167, San Antonio, Texas +1 locations
Conditions: Multiple Sclerosis
Register for Updates
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559
Recruiting
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent centra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Texas Oncology - San Antonio ( Site 8006), San Antonio, Texas
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT06585410
Recruiting
This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemip... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Texas Dermatology and Laser Specialists, San Antonio, Texas
Conditions: Cutaneous Squamous Cell Carcinoma (CSCC)
Register for Updates